A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents

Author： Mahan Charles  

Publisher： Springer Publishing Company

ISSN： 0929-5305

Source： Journal of Thrombosis and Thrombolysis, Vol.37, Iss.3, 2014-04, pp. : 271-278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future

By Kim M.H.  

Cardiac Electrophysiology Review, Vol. 7, Iss. 4, 2003-12 ,pp. : 397-400

Springer Publishing Company

Access to resources Recommend Favorite

Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine

By Mouton C.   Calderon J.   Janvier G.   Vergnes M.-C.  

Thrombosis Research, Vol. 111, Iss. 4, 2003-01 ,pp. : 273-279

Elsevier

Access to resources Recommend Favorite

Low Molecular Weight Heparin and Unfractionated Heparin in Thrombosis Prophylaxis: Meta-Analysis Based on Original Patient Data 1

By Koch A.   Ziegler S.   Breitschwerdt H.   Victor N.  

Thrombosis Research, Vol. 102, Iss. 4, 2001-05 ,pp. : 295-309

Elsevier

Access to resources Recommend Favorite

The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.

By Holst J.   Lindblad B.   Bergqvist D.   Hedner U.   Nordfang O.   Ostergaard P.  

Thrombosis Research, Vol. 86, Iss. 4, 1997-05 ,pp. : 343-348

Elsevier

Access to resources Recommend Favorite

Low-molecular-weight Heparin During Pregnancy

By Bazzan M.   Donvito V.  

Thrombosis Research, Vol. 101, Iss. 1, 2001-01 ,pp. : 175-186

Elsevier

Access to resources Recommend Favorite